Diabetic Retinopathy

Fundus Findings & Classification

Diabetic retinopathy is a chronic microvascular complication of hyperglycemia, and its fundus findings track directly with the underlying vascular pathology. The disease is broadly split into two stages: nonproliferative diabetic retinopathy (NPDR), in which damaged capillaries leak and become ischemic but no new vessels have yet formed, and proliferative diabetic retinopathy (PDR), in which retinal ischemia has become severe enough to drive pathologic neovascularization.

In NPDR, incompetent retinal capillaries leak lipid and protein, producing hard exudates: yellow- white deposits that, when they ring a focal point of leakage, are called circinate exudates and mark diabetic macular edema. Cotton wool spots and dot-blot or flame hemorrhages reflect areas of retinal ischemia and microvascular rupture. On fluorescein angiography, NPDR classically shows scattered hyperfluorescent dots at microaneurysms (focal outpouchings of weakened capillary wall where dye pools), along with areas of capillary nonperfusion and leakage across the posterior pole.

NPDR is staged by severity using the 4-2-1 rule. Severe NPDR means dense hemorrhages and microaneurysms in all four retinal quadrants, venous beading in two or more quadrants, or intraretinal microvascular abnormalities in at least one quadrant; any single one of these findings is enough to make the diagnosis. Reaching this stage carries a substantially higher one-year risk of progressing to PDR, so follow-up intervals shorten accordingly. Screening start times differ by diabetes type. A patient with type 2 diabetes needs a dilated eye exam at the time of diagnosis, since hyperglycemia may have gone unrecognized for years. A patient with type 1 diabetes can wait up to five years after diagnosis for a first exam, because retinopathy only develops after a period of sustained hyperglycemia.

Proliferative Disease

As retinal ischemia worsens, the retina upregulates VEGF (vascular endothelial growth factor) to restore perfusion. The result is new, fragile blood vessel growth, the defining feature of PDR. These vessels can arise directly from the optic disc, termed neovascularization of the disc (NVD), or elsewhere in the retina. On exam, NVD appears as an abnormal, fine, disorganized network of vessels emanating from and around the optic disc. These new vessels are structurally weak and lack the integrity of normal retinal vasculature, so they carry a high risk of rupturing into the vitreous cavity (vitreous hemorrhage) or contracting into a tractional retinal detachment. That risk is why PDR gets treated promptly rather than simply observed.

Diabetic Macular Edema

Diabetic macular edema (DME) is fluid accumulation within the macula from chronic capillary leakage, and it can occur at any stage of diabetic retinopathy, including NPDR. It sits on a separate axis of disease severity entirely from the NPDR/PDR proliferative staging. Center- involving DME is now treated primarily with intravitreal anti-VEGF agents (e.g., ranibizumab, aflibercept) rather than macular laser, which has been pushed to a second-line or adjunctive role. Anti-VEGF therapy reduces vascular permeability at its source rather than sealing individual leak points one at a time.

Panretinal Photocoagulation for PDR

Panretinal photocoagulation (PRP), also called scatter laser, is the classic treatment for PDR. Its logic is indirect: rather than targeting the new vessels themselves, PRP applies hundreds to thousands of laser burns across the peripheral retina to deliberately destroy ischemic peripheral tissue. Ablating this oxygen-starved tissue lowers the retina's overall metabolic demand, which in turn reduces the VEGF drive behind neovascularization, so the abnormal vessels regress. On fundus exam, a retina that has undergone PRP shows numerous discrete, round, pigmented laser scars scattered throughout the periphery, sparing the central macula.

This benefit comes with a real tradeoff: because PRP works by intentionally scarring functional (if ischemic) peripheral retina, it can produce peripheral visual field constriction and reduced night vision. That tradeoff is accepted because the alternative, uncontrolled neovascularization, risks vitreous hemorrhage and tractional detachment, both of which threaten central vision far more seriously. Anti-VEGF injection has emerged as an alternative or adjunct to PRP in PDR, targeting the same VEGF-driven process pharmacologically rather than through peripheral ablation.

When those complications happen anyway, pars plana vitrectomy is the surgical fallback. Two findings push a patient toward the operating room: a vitreous hemorrhage dense enough that it fails to clear with observation, and a fibrovascular tractional retinal detachment that involves or threatens the macula. Vitrectomy clears the hemorrhagic vitreous and releases the fibrovascular traction directly, fixing the mechanical problem that laser alone cannot touch.

Focal/Grid Laser for Macular Edema

Focal or grid laser photocoagulation is a distinct laser strategy from PRP, aimed squarely at the macula rather than the periphery. It directly targets leaking microaneurysms and areas of retinal thickening to reduce vascular leakage and macular edema. On fundus exam, eyes treated this way show scattered, pale-yellow, discrete round scars concentrated around the macula rather than throughout the periphery, the exact opposite distribution from PRP scarring. That contrast is a reliable way to tell, from the fundus alone, which treatment a scarred retina received.

Related Topics

Continue exploring Retina & Vitreous: